PMID- 22994875
OWN - NLM
STAT- MEDLINE
DCOM- 20130305
LR  - 20221207
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 13
IP  - 16
DP  - 2012 Nov
TI  - Tighter control of postprandial hyperglycemia with mitiglinide/voglibose 
      fixed-dose combination in Japanese patients with type 2 diabetes mellitus.
PG  - 2257-68
LID - 10.1517/14656566.2012.726614 [doi]
AB  - OBJECTIVE: The objective of this study was to compare the effects of mitiglinide, 
      voglibose and its combination on metabolic responses after a test meal in 
      Japanese patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND 
      METHODS: This randomized crossover study consisted of four periods between August 
      and November 2011. In the first period, all patients (n = 12) received water 
      alone (control period). In the next three periods, the patients received 10 mg 
      mitiglinide, 0.2 mg voglibose or a combination in a random order. MAIN OUTCOME 
      MEASURES: Postprandial metabolite/hormone levels were then measured. RESULTS: 
      Plasma glucose and serum insulin reached peak levels by 60 - 90 and 90 min, 
      respectively, after the test meal in the control group. The combination reduced 
      postprandial glucose levels compared with mitiglinide or voglibose alone, 
      particularly at 30 - 90 min, which significantly exceeded the effects of 
      mitiglinide (p < 0.05). Mitiglinide and the combination restored early insulin 
      response, whereas the combination provided an insulin-sparing effect compared 
      with mitiglinide alone. The combination improved postprandial lipid profiles, 
      combining the effects of both drugs. CONCLUSION: This study revealed marked 
      differences in the postprandial metabolic effects of mitiglinide, voglibose and 
      its combination in patients with T2DM. The combination therapy should enable 
      tighter control of postprandial hyperglycemia compared with the individual drugs.
FAU - Inoue, Masahiro
AU  - Inoue M
AD  - Sasazuka Inoue Clinic, 1-15-4 Sasazuka, Shibuya-ku, Tokyo, Japan. 
      masai426@sound.ocn.ne.jp
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120921
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Blood Glucose)
RN  - 0 (Drug Combinations)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Isoindoles)
RN  - 4L6452S749 (Inositol)
RN  - 9007-92-5 (Glucagon)
RN  - D86I0XLB13 (mitiglinide)
RN  - S77P977AG8 (voglibose)
SB  - IM
MH  - Aged
MH  - Asian People
MH  - Blood Glucose/analysis
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Combinations
MH  - Female
MH  - Glucagon/blood
MH  - Humans
MH  - Hyperglycemia/*drug therapy
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Inositol/administration & dosage/*analogs & derivatives
MH  - Insulin/blood
MH  - Isoindoles/*administration & dosage
MH  - Male
MH  - Middle Aged
EDAT- 2012/09/22 06:00
MHDA- 2013/03/06 06:00
CRDT- 2012/09/22 06:00
PHST- 2012/09/22 06:00 [entrez]
PHST- 2012/09/22 06:00 [pubmed]
PHST- 2013/03/06 06:00 [medline]
AID - 10.1517/14656566.2012.726614 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2012 Nov;13(16):2257-68. doi: 
      10.1517/14656566.2012.726614. Epub 2012 Sep 21.